Additionally, there appeared to be variability in coding practices for PSA tests as the initial population captured had nearly 20% of prostate cancer patients for whom no PSA test was recorded, leading us to restrict the population further to only capture individuals documented to have undergone at least one PSA test. This evidence concerns the gene KLK3 and prostate carcinoma.